In the recent decade, numerous TRPM8 antagonists have been reported by academic groups, as well as pharmaceutical and biotech companies, as potential drugs for neuropathic pain, inflammation, migraine, and cancer [24]. This evidence concerns the gene TRPM8 and migraine disorder.